Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Current Leases (2019 - 2025)

Historic Current Leases for X4 Pharmaceuticals (XFOR) over the last 7 years, with Q3 2025 value amounting to $1.2 million.

  • X4 Pharmaceuticals' Current Leases fell 180.03% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 180.03%. This contributed to the annual value of $1.3 million for FY2024, which is 1383.08% up from last year.
  • As of Q3 2025, X4 Pharmaceuticals' Current Leases stood at $1.2 million, which was down 180.03% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, X4 Pharmaceuticals' Current Leases registered a high of $1.4 million during Q2 2025, and its lowest value of $875000.0 during Q1 2021.
  • Its 5-year average for Current Leases is $1.1 million, with a median of $1.1 million in 2023.
  • Its Current Leases has fluctuated over the past 5 years, first surged by 3769.84% in 2021, then crashed by 826.38% in 2023.
  • X4 Pharmaceuticals' Current Leases (Quarter) stood at $1.1 million in 2021, then rose by 11.44% to $1.2 million in 2022, then fell by 8.26% to $1.1 million in 2023, then grew by 13.83% to $1.3 million in 2024, then decreased by 4.08% to $1.2 million in 2025.
  • Its Current Leases stands at $1.2 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.3 million for Q1 2025.